ClinicalTrials.gg
RecruitingNCT06481137TAVI-REVERSEUpdated Jul 1, 2024

Reversibility of Cardiac Conduction Disturbances Following TAVI

An interventional study of Electrophysiological study (EP study) and ePatch (extended Holter Monitoring) in Aortic Stenosis, Transcatheter Aortic Valve Implantation and Conduction Disturbances, sponsored by Institut d'Investigació Biomèdica de Bellvitge. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Institut d'Investigació Biomèdica de Bellvitge · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
209
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Aortic Valve Stenosis with a site in Spain — 25 open to participants now, 32 under way, 1 of them phase 3. Aortic Valve Stenosis · Spain.

Planned enrollment
19th of 37
209 · median 209
Started
2024
with 4 others
No phase
26 of 83
12 open now
Primary completion
2025-12
later than 11 of 31 live
Registered
70th of 83
by date

Among the 83 studies in Aortic Valve Stenosis with a site in Spain, this one is the 19th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2024, is one of 26 with no phase, reaches primary completion later than 11 of the 31 other live ones, and was the 70th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

25 of the 83 studies in Aortic Valve Stenosis with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Aortic Valve Stenosis with a site in Spain, or all of them as a file.
02

Study summary

The management of patients with conduction disturbances (CDs) after transcatheter aortic valve implantation (TAVI) is unclear, especially in those with de novo electrocardiographic CDs (ECG-CDs) such as left bundle branch block.

In this study, the investigators will evaluate the incidence of retrogradation of infra-Hisian CDs in patients with de novo ECG-CDs and positive electrophysiological study (EPS) 3-7 days following TAVI. In addition, the investigators will evaluate the need for cardiac pacing and the incidence of clinical events in patients with negative EPS performed 3-7 days following TAVI.

In this multicenter, longitudinal, prospective study, patients with clinical indication of EP study due to new-onset ECG-CDs after TAVI will be included. A permanent pacemaker will be implanted in patients with positive EPS and a second EPS will be performed in 30-45 days. Additionally, these patients will undergo 4-week continuous monitoring using the ePatch (Philips) long-term Holter recorder, to identify episodes of paroxysmal complete atrioventricular block. Patients with negative EP study will undergo clinical follow-up and continuous monitoring for 4 weeks.

03

Conditions studied

  • Aortic Stenosis
  • Transcatheter Aortic Valve Implantation
  • Conduction Disturbances

Keywords

  • Aortic stenosis
  • Transcatheter Aortic Valve Implantation
  • Conduction Disturbances
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with indication for electrophysiological (EP) study after TAVI implantation according to European Guidelines. Patients must have persistent electrocardiographic conduction disturbances (-CDs) that are present from day 2 after TAVI implantation (≥ 48h post-procedure):
  • De novo LBBB with QRS complex >150ms and/or PR interval ≥240ms.
  • QRS widening or post-procedural PR lengthening > 20ms in patients with baseline ECG-CDs.

Exclusion criteria

Exclusion Criteria:

  • Patients with previous pacemaker or implantable defibrillator.
  • Patients with baseline complete right bundle branch block.
  • Patients in need of cardiac resynchronization or physiological stimulation following TAVI.
  • Valve-in-valve procedures.
  • TAVI procedures in patients with severe aortic insufficiency.
  • Inability to sign the form.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
209 participants (estimated)

Study arms

  • Experimental
    Positive initial (3-7 days following TAVI) electrophysiological study (EP+)

    Permanent pacemaker implantation. Continuous ECG monitoring during 4 weeks. Second EP study 30-45 days after TAVI.

    Diagnostic Test: Electrophysiological study (EP study) · Diagnostic Test: ePatch (extended Holter Monitoring)

  • Other
    Negative initial (3-7 days following TAVI) electrophysiological study (EP-)

    Continuous ECG monitoring during 4 weeks.

    Diagnostic Test: ePatch (extended Holter Monitoring)

Interventions

  • Diagnostic testElectrophysiological study (EP study)

    Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.

  • Diagnostic testePatch (extended Holter Monitoring)

    Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI

06

What researchers measure

Primary outcomes

  1. Incidence of retrogradation

    1. Patients with positive EP: Evaluate the incidence of retrogradation of infra-Hisian conduction disturbance at 30-45 days following TAVI.

    Time frame: 30 days

  2. Need for cardiac pacing (incidence of advanced atrioventricular block)

    2. Patients with negative EP: Evaluate the rate of patients in need for cardiac pacing (incidence of clinical events related to advanced atrioventricular block).

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitari de Bellvitge
    L' Hospitalet De Llobregat, Barcelona 08097, Spain
    Recruiting
    • Hospital Universitari de Bellvitge · Contactuac@bellvitgehospital.cat · +342607500
    • Guillem Muntané Carol, MD, PhD · Principal investigator
    • Andrea di Marco, MD, PhD · Sub investigator
    • Julián Rodríguez García, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Study procotol and ICF will be shared trough PI request during the duration of the study

Supporting information: Study protocol, Informed consent form

Time frame: During the duration of the study

Access criteria: Request to the PI

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 18 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jul 1, 2024
StartActual
Jun 17, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06481137
Lead sponsor
Institut d'Investigació Biomèdica de Bellvitge
Collaborators
Hospital Universitari de Bellvitge, Hospital Universitario La Paz, Hospital Vall d'Hebron, Hospital Universitario Ramon y Cajal, Hospital Universitario A Coruna Spain, Hospital Clinico Universitario de Santiago, Hospital Universitario Central de Asturias, Hospital Universitario Marqués de Valdecilla, Hospital Clínico Universitario de Valladolid
Responsible party
Guillem Muntané Carol (Principal Investigator, Institut d'Investigació Biomèdica de Bellvitge) — Principal investigator
First posted
Jul 1, 2024
Start date
Jun 17, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 1, 2024

Study contacts

Guillem Muntané Carol, MD, PhD
Contact
gmuntanec@bellvitgehospital.cat
+342607500 ext. 7539

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion